cyprotex
the ADME Tox specialists
welcome to cyprotex

Investor News

September 29, 2011 - Board Change

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that Douglas Bates is stepping down from the board with effect from 28th September 2011. He will continue to serve the Company as a consultant. Mr Bates has served on the board since the Company's 2010 acquisition of Apredica, which Mr. Bates co-founded.

Mr Bates said: “It has been a privilege and an honour to take Apredica from conception to being successfully integrated with Cyprotex. Now that this is complete, I have decided to redirect my attention towards starting a new venture.”

The board thanks Mr. Bates for his continuing service and wishes him well in his new venture.

For further information:

Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 203 205 7500
Shaun Dobson
shaun.dobson@singercm.com
Claes Spang
claes.spang@singercm.com
www.singercm.com

FTI Consulting
Tel: +44 (0) 20 7831 3113
Ben Brewerton
Ben Atwell
Mo Noonan
cyprotex@fticonsulting.com
www.fticonsulting.com

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 22nd April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.